Theravance Biopharma (NASDAQ:TBPH) focuses on developing and commercializing novel medicines for serious illnesses. The company operates in the biopharmaceutical sector, emphasizing programs in respiratory disease, gastrointestinal disorders, and infectious diseases among others, with the aim to address unmet medical needs. Theravance Biopharma's pipeline is designed to bring transformative therapies to patients, leveraging its unique insights into pathophysiology to create innovative treatment options. The company's objectives centre on advancing its research and development to improve patient outcomes and deliver sustainable growth.